Portal de Periódicos da CAPES

Cardiac transplant hypertension

1990; Elsevier BV; Volume: 65; Issue: 1 Linguagem: Inglês

10.1016/0002-9149(90)90035-y

1879-1913

Randall C. Starling, Robert J. Cody,

Cardiac Ischemia and Reperfusion

C ardiac transplantation is an effective and accepted form of treatment for end-stage heart failure. The growth of heart transplantation has occurred coincident with the introduction of the immunosuppressive agent cyclosporine and subsequent improvement in survival rates. The 1988 registry report of the International Society for Heart Transplantation reported a 79% 5-year actuarial survival for patients treated with cyclosporine.’ Although rejection and infection account for >50% of deaths after transplant, cardiac etiologies now comprise 25%. Accelerated graft coronary artery disease is a growing concern as long-term survival improves. Also, it is increasingly clear from articles, abstracts and anecdotal reports that rampant, refractory hypertension is a major clinical problem and concern in heart transplant recipients. The goal of this review is to discuss what is known about cardiac transplant hypertension and the threat it may pose to long-term survival.